about
Antipsychotics for fibromyalgiaAnticonvulsants for fibromyalgiaSerotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndromeAntipsychotics for fibromyalgia in adultsHigh-Resolution Ultrasonography of the Superficial Peroneal Motor and Sural Sensory Nerves May Be a Non-invasive Approach to the Diagnosis of Vasculitic NeuropathyTransient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients[Methodological fundamentals for the development of the guideline].Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry diseaseLocal and systemic cytokine expression in patients with postherpetic neuralgia.Systematic review with meta-analysis: cytokines in fibromyalgia syndrome.IL-4 deficiency is associated with mechanical hypersensitivity in mice.Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls[Etiology and pathophysiology of fibromyalgia syndrome].[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial.High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know.Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control studyIncreased cortical activation upon painful stimulation in fibromyalgia syndromeSelf-administered version of the Fabry-associated pain questionnaire for adult patients.Expectation-Driven Text Extraction from Medical Ultrasound Images.Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.Amplitudes of Pain-Related Evoked Potentials Are Useful to Detect Small Fiber Involvement in Painful Mixed Fiber Neuropathies in Addition to Quantitative Sensory Testing - An Electrophysiological Study.Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.Determinants of white matter hyperintensity burden in patients with Fabry disease.Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.Cytokine regulation in animal models of neuropathic pain and in human diseases.microRNAs in nociceptive circuits as predictors of future clinical applications.Status of immune mediators in painful neuropathies.Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease.Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.Pain: from new perspectives to novel treatments.Small fiber pathology--a culprit for many painful disorders?Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro.Neuropathic pain in two-generation twins carrying the sodium channel Nav1.7 functional variant R1150W.
P50
Q24186761-491492CE-4E56-4FCB-9C2F-4ABB9FD30970Q24197464-3D13CCC9-63A7-435F-872B-9F259D76AF3BQ24201799-A77CADF2-84C9-41FD-A6B4-6F6F1B2C9B71Q26471557-AFA6E4A0-1F70-457A-8463-D433845379AAQ27318401-AF5C6DCD-3F1C-4096-B132-224CE1460D6EQ28741571-F11A6EB4-CDC4-42FE-83F5-0A3FB857E90AQ33331884-51AE25F4-3621-4A68-B53A-129704478273Q33747253-352828EE-C2B9-4212-8B7F-138DDC09AC33Q33853780-20D2E5E6-50C8-4D7F-936B-9C79BDE91E18Q34051040-B160971C-8017-4CB8-98FB-E9B56458F58AQ34060700-8DD30872-BDDD-415D-8F50-C071603E108AQ34099062-8EC25354-C6BB-4977-9767-F1F593A6F16BQ34103791-640B97E1-63CF-4FFA-9D37-0EBFFE538685Q34132086-ABA38991-5E50-4C6D-9C1A-6B1F4B0C9E44Q34246455-9AF32866-067E-49DD-AF0D-7E88E6A9454DQ34285824-14AB9AB5-7029-4B83-8663-6B4BBA1461CAQ34285830-F1185A9A-2D45-4668-A41B-A059DFC8E4EEQ34301601-6B03FB2F-6346-4D5D-B4AE-727F5CA4B59DQ34726023-DE98186D-29AA-424E-B8D0-DC85EFD1D8B1Q34739186-D580FA80-45F3-4A24-B949-0730D81CD440Q35815368-39F6DA4B-B9B2-4C9B-B450-9DC6B8140ED7Q36069971-E7C15C6A-17CA-4EF9-BB92-4A88BE564C50Q36117638-F12A1D20-9B28-47BF-B217-737422892DA2Q36193984-45B8EE5E-B164-43EB-9413-0E5CEA196A96Q36349888-A7C76B30-95A2-470A-B322-BD34588085AEQ36624746-EE4BD806-15E3-4686-9A05-DD4B8EB01423Q36819212-55A2C9D8-5491-419D-934D-09FB94D27C11Q36918864-54AE6E64-84C0-46D4-9712-1736DB253DD4Q37054755-BAAF3A3D-C51C-47BC-BB17-34A4A4C48C20Q37115269-769F959A-A243-4A3D-B659-54C8C9BECB53Q37134876-A9346CC2-D35B-4517-9D33-D30FDCD695EDQ37233099-5C817B0D-7218-45DC-9593-1537CE2C94A2Q37270867-68D20EEE-4A8E-4402-A50E-DBBAA9987878Q37352268-59ED5792-82AD-43C1-BE02-9BCDB0EE7E7DQ37521065-57D6AF26-AB45-49A9-9D40-7215E1C04CBEQ37670334-CBC5C408-3054-4DB4-8771-E9AF94969E60Q38286464-6CA1EB1C-E585-4D00-92D2-7DF8DC341319Q38701127-A1737F4C-053E-4723-A913-487DB48671A5Q38765969-CD45B7FE-C8D6-43A3-AE6B-D22BBA4C4CF8Q39202602-C84C5D08-12A8-416A-994C-34811A8FABC8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nurcan Üçeyler
@ast
Nurcan Üçeyler
@en
Nurcan Üçeyler
@es
Nurcan Üçeyler
@sl
type
label
Nurcan Üçeyler
@ast
Nurcan Üçeyler
@en
Nurcan Üçeyler
@es
Nurcan Üçeyler
@sl
prefLabel
Nurcan Üçeyler
@ast
Nurcan Üçeyler
@en
Nurcan Üçeyler
@es
Nurcan Üçeyler
@sl
P106
P31
P496
0000-0001-6973-6428